Biotech | April 13, 2022
Novel Covid-19 vaccine may protect the immunocompromised
The peptide-based vaccine induces a t cell-dependent response
The peptide-based vaccine induces a t cell-dependent response
Nuvaxovid is the first protein-based Covid-19 vaccine authorized for use in Switzerland
This could be a game-changer for the prevention of the disease; seeing more doses of the life-saving jab reach more girls
Pharmapack trends are a key barometer of global device and packing opportunities in 2022
Collaboration awarded €3 million grant by the Bill & Melinda Gates Foundation
Both mRNA-1020 and mRNA-1030 target hemagglutinin and neuraminidase antigens, two major influenza surface glycoproteins that are essential across the viral life cycle
Collaboration to target bacterial and viral pathogens including HIV, SARS-CoV-2, antimicrobial-resistant pathogens, and tuberculosis
Veeda Clinical Research will submit data in an application for Emergency Use Authorisation
About 96% of all 15+ population in the country have received at least one Covid-19 vaccine dose while about 83% of 15+ population has received both the doses
The recombinant nanoparticle-based rabies G protein vaccine is prepared using virus-like particle technology.
Subscribe To Our Newsletter & Stay Updated
